Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price hit a new 52-week low on Friday. The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 1,500 shares trading hands. The stock had previously closed at C$0.03.
Quest PharmaTech Price Performance
The stock has a market capitalization of C$3.38 million, a P/E ratio of 0.68 and a beta of -0.75. The company’s 50 day simple moving average is C$0.02 and its two-hundred day simple moving average is C$0.03. The company has a debt-to-equity ratio of 4.35, a current ratio of 0.40 and a quick ratio of 0.52.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Stories
- Five stocks we like better than Quest PharmaTech
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
